RealTime Dynamix: Psoriasis Q4 is the third report in a three-part 2016 series focusing on current and anticipated future trends in the PsO market. Report content includes current and future patient share, treatment satisfaction, industry contact rates, awareness and familiarity with products in development, sources of information about development compounds, statement agreements, line of therapy analysis, treatment discontinuations, brand barriers, impact of biosimilars, and a detailed look at dermatologists’ adoption of Taltz. Major in-line brands covered include Cosentyx, Enbrel, Humira, Otezla, Remicade, Stelara, and Taltz. PsO pipe-line agents covered include brodalumab, guselkumab, tildrakizumab, tofacitinib, and the recently approved biosimilar, Inflectra.

Download Report Overview

About Spherix Global Insights
Spherix Global Insights is a business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.

For more information contact:
Telephone: (800) 661-0571